[Complications of intracavernous pharmacologic infusion in impotence. Long-term results].
The large scale employment in recent years of vasoactive drugs in the treatment of impotence forms the basis for a significant statistical study on incidence of complications and collateral effects. We studied 658 patients submitted to ICF (intracavernous pharmacoinfusion) diagnostic and therapeutic in the last 6 years (1986-1992). The patients have been shared groups according to the period and the treatment: in 226 cases we have utilized papaverine, in 224 cases phentolamine-papaverine association and in 208 cases prostaglandin E1. In the last group the complications have been lower: echymosis and haematoma 0.5%, priapism 1.5%, intracavernous fibrosis 1%, fibrotic knots 0.5%. In conclusion we confirm the validity of treatment with PGE1 intracavernous infusion.
Pastorini
S
S
Divisione di Urologia, Ospedale Mauriziano Umberto I, Torino.
Marino
G
G
Cocimano
V
V
Griffa
D
D
Pugno
E
E
D000328:Adult; D000368:Aged; D000527:Alprostadil / Q000008:administration & dosage / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D007172:Erectile Dysfunction / Q000188:drug therapy*; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D010208:Papaverine / Q000008:administration & dosage / Q000009:adverse effects*; D010409:Penile Diseases / Q000139:chemically induced* / Q000453:epidemiology; D010646:Phentolamine / Q000008:administration & dosage / Q000009:adverse effects*
D010208:Papaverine; D000527:Alprostadil; D010646:Phentolamine
Le complicanze del trattamento FIC nell'impotenza. Risultati a distanza.